We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Reviewers Recommend Against Approval of J&J, Bayer’s Xarelto
FDA Reviewers Recommend Against Approval of J&J, Bayer’s Xarelto
September 6, 2011
FDA reviewers are recommending against approval of Johnson & Johnson (J&J) and Bayer AG’s oral anticoagulant Xarelto as clinical trials, while largely favorable, have not shown superiority to warfarin.